Early costs and complications of first-line low-grade glioma treatment using a large national database: Limitations and future perspectives.

ABSTRACT:

Introduction

Diffuse Low-grade gliomas (DLGG, WHO Grade II) are a heterogenous group of tumors comprising 13-16% of glial tumors. While maximal safe resection is endorsed as the best approach to DLGG, compared to more conservative interventions like stereotactic biopsy, the added costs and risks have not been systematically evaluated. The purpose of this study was to better understand the complication rates and costs associated with each intervention.

Methods

A retrospective cohort study using data from the IBM Watson Health MarketScan® Commercial Claims and Encounters database was conducted, using the International Classification of Diseases, Ninth Revision (ICD-9) codes corresponding to DLGG (2005-2014). Current Procedure Terminology, 4th Edition (CPT-4) code

SUBMITTER: Tuohy K 

PROVIDER: S-EPMC9935584 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature